HomeMedia Releases & News 2019

Media Releases & News 2019

San Diego, 09.07.2019

Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers

Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for treatment of patients with KRAS-mutated metastatic Colorectal Cancer (mCRC). Highly recognized unmet need for 50% of mCRC patients who harbor the KRAS mutation, given current treatment response rate of only 5%. Trovagene to leverage proprietary Precision Cancer Medicine™ tumor genomic technology to assess early indication of treatment response. Trovagene licensed onvansertib (also known as NMS-1286937 and PCM-075) from Nerviano Medical Sciences.
Leggi tutto +